# Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years

DOI: 10.1111/cas.12106
Cancer Science, 2013, 104, 465-72.

| # | Paper | IF | Citations |
|---|---|---|---|
| 31 | Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. *Cancer Science*, **2013**, 104, 465-72 | 6.9 | 29 |
| 30 | Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule. *Human Vaccines and Immunotherapeutics*, **2014**, 10, 2438-45 | 4.4 | 12 |
| 29 | Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection. *Journal of Clinical Virology*, **2014**, 59, 246-9 | 14.5 | 46 |
| 28 | Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil( )): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts. *Drugs*, **2014**, 74, 1253-83 | 12.1 | 44 |
| 27 | HPV catch-up vaccination of young women: a systematic review and meta-analysis. *BMC Public Health*, **2014**, 14, 867 | 4.1 | 20 |
| 26 | ?????????????????? ?????????????????2013 *Journal of Otolaryngology of Japan*, **2014**, 117, 614-630 | 0.1 | 5 |
| 25 | Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil ): a guide to its use in the EU. *Drugs and Therapy Perspectives*, **2015**, 31, 1-8 | 1.5 | 0 |
| 24 | Recent progress in vaccination against human papillomavirus-mediated cervical cancer. *Reviews in Medical Virology*, **2015**, 25 Suppl 1, 54-71 | 11.7 | 29 |
| 23 | Literature review of vaccine-related adverse events reported from HPV vaccination in randomized controlled trials. *Basic and Clinical Andrology*, **2016**, 26, 16 | 2.8 | 4 |
| 22 | Serious adverse events after HPV vaccination: a critical review of randomized trials and post-marketing case series. *Clinical Rheumatology*, **2017**, 36, 2169-2178 | 3.9 | 22 |
| 21 | Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. *Expert Review of Vaccines*, **2018**, 17, 1085-1091 | 5.2 | 64 |
| 20 | Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. *The Cochrane Library*, **2018**, 5, CD009069 | 5.2 | 165 |
| 19 | HPV16 -miRNAs in cervical cancer and the anti-tumor role played by miR-5701. *Journal of Gene Medicine*, **2019**, 21, e3126 | 3.5 | 11 |
| 18 | Cervical intraepithelial neoplasia grade 3 in a patient following Gardasil vaccination. *BMJ Case Reports*, **2019**, 12, | 0.9 | 1 |
| 17 | Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. *Journal of Infection and Chemotherapy*, **2019**, 25, 520-525 | 2.2 | 2 |
| 16 | Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants. *Papillomavirus Research (Amsterdam, Netherlands)*, **2020**, 10, 100205 | 4.6 | 1 |
| 15 | The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis. *BMC Public Health*, **2020**, 20, 691 | 4.1 | 9 |

| | | | |
|---|---|---|---|
| 14 | HPV vaccination and cancer prevention. *Best Practice and Research in Clinical Obstetrics and Gynaecology*, **2020**, 65, 109-124 | 4.6 | 14 |
| 13 | Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches. *BMC Infectious Diseases*, **2020**, 20, 482 | 4 | 0 |
| 12 | Will HPV vaccination prevent cervical cancer?. *Journal of the Royal Society of Medicine*, **2020**, 113, 64-78 | 2.3 | 11 |
| 11 | Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case-control study. *Cancer Science*, **2021**, 112, 839-846 | 6.9 | 7 |
| 10 | Risk Assessment and Control on Vaccine-Preventable Diseases. **2021**, 35-61 | | |
| 9 | Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19. *Vaccines*, **2021**, 9, | 5.3 | 3 |
| 8 | The comparative safety of human papillomavirus vaccines: A Bayesian network meta-analysis. *Journal of Medical Virology*, **2022**, 94, 729-736 | 19.7 | 1 |
| 7 | Association between free testosterone levels and anal human papillomavirus types 16/18 infections in a cohort of men who have sex with men. *PLoS ONE*, **2015**, 10, e0119447 | 3.7 | 1 |
| 6 | Human papillomavirus vaccine efficacy in the prevention of anogenital warts: systematic review and meta-analysis. *Salud Publica De Mexico*, **2017**, 59, 84-94 | 1.7 | 10 |
| 5 | Efficacy of L1 Protein Vaccines Against Cervical and Vaginal Cancer: A Systematic Review and Meta-Analysis. *Iranian Red Crescent Medical Journal*, **2016**, 19, | 1.3 | 2 |
| 4 | HPV Immunization. **2021**, 457-466 | | |
| 3 | HPV-assoziierte Neoplasien: Wie die Impfprvention gefdert werden kann. | | |
| 2 | The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age.. *Human Vaccines and Immunotherapeutics*, **2022**, 1-6 | 4.4 | 0 |
| 1 | Updates on HPV Vaccination. **2023**, 13, 243 | | 0 |